Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a222299aec56b965

Jump to content

electroCore

From Wikipedia, the free encyclopedia

electroCore, Inc. (Nasdaq: ECOR) is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD.[1] The current chief executive officer is Daniel S. Goldberger.[2] electroCore[3] has one product called gammaCore,[4][5] a non-invasive, commercially available product that uses vagus nerve stimulation.[6]

History

[edit]

The company was co-founded by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD, in 2005.[1]

In 2018, electroCore, Inc. went public with a $78 million IPO.[7]

On March 27, 2020, electroCore announced a common stock purchase agreement of up to $25 million with Chicago-based institutional investor Lincoln Park Capital Fund, LLC.[8]

In 2025, the company acquired NeuroMetrix, adding the Quell electrical nerve stimulation platform to its product portfolio.[9]

Products

[edit]

gammaCore Sapphire CV

[edit]

In July 2020, the FDA gave an emergency COVID-19 authorization for gammaCore Sapphire CV, a vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma.[10]

Truvaga

[edit]

A VNS product owned by Electrocore.[11]

References

[edit]
  1. 1 2 "electroCore Inc. Company & People | ECOR". Barron's. Retrieved 2024-12-12.
  2. "Nerve stimulation device maker electroCore goes public with $78M IPO | FierceBiotech". www.fiercebiotech.com. Retrieved 2019-03-06.
  3. "This hand-held device is approved to treat cluster headaches". NBC News. Retrieved 2019-03-06.
  4. "ElectroCore wins cluster headache FDA 510(k) indication for GammaCore". MassDevice. 2018-11-28. Retrieved 2019-03-06.
  5. "Nerve Stimulator Approved for Cluster Headache". Pain News Network. Retrieved 2019-03-06.
  6. "Term Sheet -- Friday, June 22". Fortune. Retrieved 2019-03-06.
  7. Hale, Conor (2018-06-22). "Nerve stimulation device maker electroCore goes public with $78M IPO | Fierce Biotech". www.fiercebiotech.com. Retrieved 2024-12-16.
  8. "BRIEF-electroCore Announces Common Stock Purchase Agreement For Up To $25 Mln With Lincoln Park Capital". Reuters. 2020-03-27. Retrieved 2020-03-31.
  9. Hale, Conor (2024-12-20). "ElectroCore buys NeuroMetrix and its Quell fibromyalgia wearable". www.fiercebiotech.com. Retrieved 2026-07-22.
  10. electroCore (2020-07-13). "electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients". GlobeNewswire News Room. Retrieved 2020-07-15.
  11. https://www.truvaga.com/vagus-nerve-science/